methyl 1-hydroxy-4-nitro-2-naphthoate | 708238-05-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: methyl 1-hydroxy-4-nitro-2-naphthoate
• 英文别名: Methyl 1-hydroxy-4-nitronaphthalene-2-carboxylate
• CAS: 708238-05-5
• 化学式: C₁₂H₉NO₅
• 分子量: 247.207
• InChiKey: BKJGTMMYYDMXBB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  92.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 1-hydroxy-4-nitro-2-naphthoate 在 sodium hydroxide 、 五氯化磷 、 苯 作用下， 生成 1-hydroxy-4-nitro-[2]naphthoyl chloride
  参考文献：
  名称：

  Rao, Proceedings - Indian Academy of Sciences, Section A, 1938, vol. 7, p. 261,263

  摘要：

  DOI：
• 作为产物：
  描述：

  甲基-1-羟基-2-萘甲酸盐 在 硝酸 、 溶剂黄146 作用下， 以 乙腈 为溶剂， 反应 2.0h， 生成 methyl 1-hydroxy-4-nitro-2-naphthoate
  参考文献：
  名称：

  몰루긴 유도체 화합물, 및 이를 포함하는 염증성 장질환의 예방 또는 치료용 약학 조성물

  摘要：

  这项发明涉及含有molugin或molugin衍生物作为有效成分的用于治疗炎症性肠疾病的药物组合物。更详细地说，涉及molugin衍生物化合物，其用以下化学式I表示。[化学式I] X代表C-C烷基取代基或非取代胺基，或氧；R代表氢基，氟基取代或非取代C-C烷基，或氟基；R代表氢基，吗啉取代或非取代C-C烷基，或N-(C-C烷基)取代或非取代哌啶基；R代表氢基，或乙烯基；R代表氢基（仅限X为胺基的情况），或C-C烷基；若R为乙烯基且同时R为烷基，则与相邻的R结合形成6元杂环。

  公开号：

  KR20190079852A

文献信息

• 몰루긴 유도체 화합물, 및 이를 포함하는 염증성 장질환의 예방 또는 치료용 약학 조성물
  申请人：KOREA PHARMA CO., LTD. 주식회사한국파마(119980043604) Corp. No ▼ 180111-0059112BRN ▼124-81-15899

  公开号：KR20200041852A

  公开（公告）日：2020-04-22

  본 발명은 염증성 장질환의 치료제로 유용하게 사용할 수 있는 몰루긴 또는 몰루긴 유도체를 유효성분으로 함유하는 염증성 장질환 치료용 약학조성물에 관한 것이다. 보다 상세히는, 하기 화학식 Ⅰ로 표현되는 몰루긴 유도체 화합물에 관한 것이다. [화학식 Ⅰ] X는 C-C 알킬기 치환 또는 비치환 아민기, 또는 산소; R은 수소기, 불소기 치환 또는 비치환 C-C 알킬기, 또는 불소기; R는 수소기, 몰포린 치환 또는 비치환 C-C 알킬기, 또는 N-(C-C 알킬)치환 또는 비치환 피페리딘기; R은 수소기, 또는 비닐기; R는, 수소기(단, X가 아민기인 경우에 한함), 또는 C-C 알킬기이고; R가 비닐기이고 동시에 R가 알킬기이면, 인접한 R와 결합하여 6원 불포화 헤테로 고리를 형성한다.

  这项发明涉及含有molugin或molugin衍生物作为有效成分的用于治疗炎症性肠疾病的药物组合物。更详细地说，涉及一种化合物，其化学式表示为I。 [化学式I] X代表C-C烷基取代基或非取代氨基，或氧；R代表氢基，氟基取代基或非取代C-C烷基，或氟基；R代表氢基，吗啡取代基或非取代C-C烷基，或N-(C-C烷基)取代基或非取代哌啶基；R代表氢基，或乙烯基；R代表氢基（仅限X为氨基的情况），或C-C烷基；如果R为乙烯基且同时R为烷基，则与相邻的R结合形成6元不饱和杂环。
• Einhorn; Pfyl, Justus Liebigs Annalen der Chemie, 1900, vol. 311, p. 55
  作者：Einhorn、Pfyl

  DOI：——

  日期：——
• Onset of spinal block is more rapid with isobaric than hyperbaric bupivacaine
  作者：René Martin、Chantal Frigon、Angelo Chrétien、Jean-Pierre Tétrault

  DOI：10.1007/bf03020730

  日期：2000.1

  Purpose: To compare isobaric with hyperbaric 9.75 mg bupivacaine injected intrathecally, and to evaluate the effects of subsequent injection of lidocaine 2% into the epidural space.Methods: Patients in group I (n = 30) received isobaric 9.75 mg bupivacaine and in group 2 (n = 30) hyperbaric 9.75 mg bupivacaine injected into the subarachnoid space in a combined spinal-epidural technique, They were undergoing urological, gynecological, orthopedic, gastro-intestinal or vascular surgery. Using a double blind technique, the followings parameters were measured: cutaneous analgesia to pinprick, motor blockade, time for two segment regression, time for complete regression of the motor block, quality of anesthesia. In 12 patients the effect of epidural injections of 3 ml lidocaine 2% was observed.Results: Motor and sensory block developed more rapidly (five minutes) in the isobaric group (P < 0.05). Maximum upper level (T7 +/- 2), two-segment regression (52 min in both groups), motor recovery (160 vs 157 min), and quality of anesthesia did not differ between the two groups. Thirty nine epidural injections of 3 mi lidocaine 2% were given in 12 patients 10 min after spinal injection, 28 were in the hyperbaric group (P < 0.05). Twenty six of the epidural injections produced an increase in sensory block of 0 or 1 dermatome, and 13, of 2 or more.Conclusion: The block developed more rapidly in the isobaric group, but both isobaric and hyperbaric 9.75 mg bupivacaine produced adequate upper levels of analgesia for surgery. The effect of epidural injections of 3 mi lidocaine 2% was usually minimal.
• [EN] NOVEL SPECIFICALLY SUBSTITUTED THIOPHENOLIC COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS THIOPHÉNOLIQUES À SUBSTITUTION SPÉCIFIQUE
  申请人：[en]NERVIANO MEDICAL SCIENCES S.R.L.

  公开号：WO2024028169A1

  公开（公告）日：2024-02-08

  The present invention relates to novel thiophenolic compounds (I) which are useful in the treatment of proliferative and/or hyper-proliferative diseases. Preferably, the compounds of the present invention are endowed with inhibitory activity against Werner helicase protein (WRN, RECQL2) and are thus useful in the therapy or treatment of cancer. Furthermore, the invention relates to the use of the compounds according to the invention to inhibit the activity of one or more helicases, preferably including Werner Helicase (WRN) and pharmaceutical composition comprising such compounds. Formula (I).
• Syntheses and anti-inflammatory activity of azamollugin derivatives
  作者：Hitomi Nishino、Yuki Nakajima、Yoshiaki Kakubari、Nakata Asami、Jun Deguchi、Alfarius Eko Nugroho、Yusuke Hirasawa、Toshio Kaneda、Yoko Kawasaki、Yukihiro Goda、Hiroshi Morita

  DOI：10.1016/j.bmcl.2015.11.081

  日期：2016.1

  Oxomollugin (2) is a degradation product of mollugin (1) and a potent inhibitor of NO-production including nuclear factor kappa B signals. In our endeavor to develop a potent anti-inflammatory compound, we synthesized several aza-derivatives of oxomollugin (2) and evaluated their NO-production inhibitory activity. Azamollugin (3) showed a potent inhibitory activity, and its activity (IC50 0.34 mu M) was proved to be more potent than that of oxomollugin (2, IC50 1.3 mu M). (C) 2015 Elsevier Ltd. All rights reserved.